Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids

Moschos, Sterghios A; Williams, Andrew E; Perry, Mark M; Birrell, Mark A; Belvisi, Maria G; Lindsay, Mark A
January 2007
BMC Genomics;2007, Vol. 8, p1
Academic Journal
Background: At present, nothing is known of the role of miRNAs in the immune response in vivo despite the fact that inflammation is thought to underlie multiple acute and chronic diseases. In these circumstances, patients are commonly treated with corticosteroids such as dexamethasone. Results: To address this question, we have examined the differential expression of 104 miRNAs using real-time PCR during the innate immune response in mouse lung following exposure to aerosilised lipopolysaccharide (LPS). Following challenge, we observed rapid and transient increase in both the mean (4.3-fold) and individual levels of miRNA expression (46 miRNAs) which peaked at 3 hrs. Crucially, this increase was correlated with a reduction in the expression of tumour necrosis factor (TNF)-α, keratinocyte-derived chemokine (KC) and macrophage inflammatory protein (MIP)-2, suggesting a potential role for miRNAs in the regulation of inflammatory cytokine production. Examination of the individual miRNA expression profiles showed time dependent increases in miR-21, -25, -27b, -100, 140, -142-3p, -181c, 187, -194, -214, -223 and -224. Corticosteroid studies showed that pre-treatment with dexamethasone at concentrations that inhibited TNF-α production, had no effect either alone or upon the LPS-induced miRNA expression profile. Conclusion: We have shown that the LPS-induced innate immune response is associated with widespread, rapid and transient increases in miRNA expression in the mouse lung and we speculate that these changes might be involved in the regulation of the inflammatory response. In contrast, the lack of effect of dexamethasone in either control or challenged animals implies that the actions of glucocorticoids per se are not mediated through changes in miRNAs expression and that LPS-induced increases in miRNA expression are not mediated via classical inflammatory transcription factors.


Related Articles

  • Overcoming Reduced Glucocorticoid Sensitivity in Airway Disease. Marwick, John A.; Adcock, Ian M.; Kian Fan Chung // Drugs;2010, Vol. 70 Issue 8, p929 

    There is a considerable and growing unmet medical need in respiratory disease concerning effective anti-inflammatory therapies for conditions such as severe asthma, chronic obstructive pulmonary disease and cystic fibrosis. These diseases share a predominant characteristic of an enhanced and...

  • In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells. Hu, Yadong; Dong, Chunsheng; Yue, Yan; Xiong, Sidong // Archives of Virology;Sep2014, Vol. 159 Issue 9, p2411 

    Interleukin (IL)-35 is a new member of the IL-12 cytokine family. The suppressive role of IL-35 in the immune response to parasitic and bacterial infections and in autoimmunity has been demonstrated in terms of its anti-inflammatory properties. However, the functional role of IL-35 in viral...

  • Overlap Chronic Placental Inflammation Is Associated with a Unique Gene Expression Pattern. Raman, Kripa; Wang, Huaqing; Troncone, Michael J.; Khan, Waliul I.; Pare, Guillaume; Terry, Jefferson // PLoS ONE;7/24/2015, Vol. 10 Issue 7, p1 

    Breakdown of the balance between maternal pro- and anti-inflammatory pathways is thought to allow an anti-fetal maternal immune response that underlies development of chronic placental inflammation. Chronic placental inflammation is manifested by the influx of maternal inflammatory cells,...

  • Immune Response Indicated by Expressing of IL-2 and IL-10 in Cervical Cancer. Prayitno, Adi; Astirin, Okid Parama; Putra, Suhartono Taat // Journal of Cancer Therapy;Apr2014, Vol. 5 Issue 5, p420 

    Introduction: Interleukin-2 (IL-2) is multiple which functions during an inflammatory response. Inflammation is a critical component of cancer progression. IL-10 is the most important cytokine with anti-inflammatory properties. Cancer patients typically show depression of both cellular and...

  • Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease. Stoll, Lynn L.; Denning, Gerene M.; Weintraub, Neal L. // Current Pharmaceutical Design;Nov2006, Vol. 12 Issue 32, p4229 

    Cardiovascular disease ranks among the leading causes of morbidity and mortality in adult populations in the Western world. Significant progress in understanding the etiology of cardiovascular disease has come from recent recognition that chronic inflammation plays a key role in its development....

  • Immunomodulatory and Anti-Inflammatory Activities of Chicken Cathelicidin-2 Derived Peptides. van Dijk, Albert; van Eldik, Mandy; Veldhuizen, Edwin J. A.; Tjeerdsma-van Bokhoven, Hanne L. M.; de Zoete, Marcel R.; Bikker, Floris J.; Haagsman, Henk P. // PLoS ONE;2/5/2016, Vol. 11 Issue 2, p1 

    Host Defence Peptides and derived peptides are promising classes of antimicrobial and immunomodulatory lead compounds. For this purpose we examined whether chicken cathelicidin-2 (CATH-2)-derived peptides modulate the function and inflammatory response of avian immune cells. Using a chicken...

  • Editorial. Vesce, Fortunato // Current Pharmaceutical Design;11/21/2010, Vol. 16 Issue 32, p3538 

    No abstract available.

  • Glucocorticosteroids (Glucocorticoids). Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p261 

    A definition of the term "glucocorticosteroids" is presented. They refer to steroid hormones with immunomodulatory and antiinflammatory properties.

  • Targeting Th2 Cells in Asthmatic Airways. Caramori, Gaetano; Ito, Kazuhiro; Adcock, Ian M. // Current Drug Targets - Inflammation & Allergy;Sep2004, Vol. 3 Issue 3, p243 

    The most effective anti-asthmatic drugs currently available include inhaled β2-agonists and glucocorticoids and control asthma in about 95% of patients. The current asthma therapies are not cures and symptoms return soon after the treatment is stopped even after long-term therapy. In...


Other Topics